Clinical trials: Chronic Obstructive Pulmonary
Chronic Obstructive Pulmonary Disease
Exacerbation Study
This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks
- Trial name
- INVIGORATE (NCT00845728)
- Testing
- Indacaterol 150 µg, Tiotropium
- Where
- 423 sites in Argentina, Australia and 38 more
- Volunteers
- 3,439 people
- Sponsor
- Novartis Pharmaceuticals
COPD
A Home-based Module to Promote Mindful Breathing Awareness for COPD Patients
The purpose of this study is to develop a mindful breathing module to an already effective and developed home based rehabilitation program for guiding COPD patients in a mindful breathing practice and further palliate…
- Trial name
- NCT04517500
- Testing
- Home-based pulmonary rehabilitation program, Mindful breathing module, Health coaching
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Mayo Clinic
Chronic Obstructive Pulmonary Disease
TOPIC Trial for COPD
The study is a randomized, double-blind, placebo-controlled, multiple-dose, pilot study of orally-administered ivacaftor in subjects with chronic obstructive pulmonary disease.
- Trial name
- NCT02135432
- Testing
- Ivacaftor
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Alabama at Birmingham
Chronic Obstructive Pulmonary Disease
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and efficacy of the fixed combination product QVA149 versus the component products QAB149 and NVA237, administered concurrently, in patients that have moderate to severe chronic obstructive pulmonary…
- Trial name
- BEACON (NCT01529632)
- Testing
- QVA149, NVA237, QAB149
- Where
- 26 sites in Austria, Denmark and 3 more
- Volunteers
- 193 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population
The purpose of this study is to evaluate the pharmacodynamics (bronchodilation) of single doses of inhaled LAS100977 in COPD patients.
- Trial name
- NCT01425814
- Testing
- LAS100977, Reference
- Where
- 8 sites in Germany
- Volunteers
- 87 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor
The study is a Phase 2 Study to establish the safety and efficacy of a drug called Ivacaftor (VX-770) in patients with chronic obstructive pulmonary disease (COPD), chronic bronchitis, and acquired CFTR dysfunction as detected by…
- Trial name
- NCT03085485
- Testing
- Ivacaftor 150 MG
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
COPD, Emphysema
Mechanistic Effects of Health Coaching to Reduce Chronic Obstructive Pulmonary Disease (COPD) Hospitalizations
The researchers are trying to explore the benefit of Health Coaching on patients with severe symptoms of COPD.
- Trial name
- NCT03837847
- Testing
- Health Coaching Calls, Control
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Mayo Clinic
Chronic Obstructive Pulmonary Disease
Evaluation of a Portable Oxygen Concentrator During Ambulation for Patients Who Require Supplemental Oxygen (POC-LEAN)
Prospective randomized study with a cross-over design. Mobi™ is a relatively new POC in the market and thus it is valuable to collect data from COPD patients using supplemental oxygen, and their use on Mobi™.
- Trial name
- NCT04107493
- Testing
- Portable Oxygen Cylinder, Mobi
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- ResMed
Chronic Obstructive Pulmonary Disease, COPD
Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients
This mechanistic study is a single-center, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effect of dual bronchodilation with QVA149 on cardiac and lung function parameters in hyperinflated COPD…
- Trial name
- CLAIM (NCT02442206)
- Testing
- QVA149
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD
The main objective of the current trial is to investigate safety, tolerability, pharmacokinetics and effect on inflammation of oral BI 1026706 administered twice daily for 4 weeks in patients with COPD.
- Trial name
- NCT02642614
- Testing
- BI 1026706
- Where
- 10 sites in Denmark, Germany and 2 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents
This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are receiving erythropoietic agents…
- Trial name
- NCT00224042
- Testing
- Sodium Ferric Gluconate complex in sucrose, Ferrous sulfate tablets
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Watson Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I
The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.
- Trial name
- NCT00793624
- Testing
- Olodaterol (BI 1744), Formoterol
- Where
- 93 sites in Argentina, Brazil and 18 more
- Volunteers
- 906 people
- Sponsor
- Boehringer Ingelheim
COPD
Imaging Regional Lung Defect Severity
The purpose of this study is to develop and evaluate the usefulness of magnetic resonance imaging (MRI) using inert perfluorinated gases mixed with oxygen for regional assessment of pulmonary function.
- Trial name
- DIAL1001004 (NCT01640288)
- Testing
- Perfluorinated Gas/Oxygen Mixture, High Resolution CT of the Chest
- Where
- United States
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- Hal C Charles
COPD
Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD
This is a Randomized, Phase III, Two-period, Open-label, Chronic-dosing (7 Days), Multi-center, Crossover Study to Assess the Efficacy of PT003 in Subjects with Moderate to Severe COPD with and without a Valved Holding Chamber.
- Trial name
- NCT02454959
- Testing
- GFF MDI (PT003) with Aerochamber, GFF MDI (PT003) without Aerochamber
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with…
- Trial name
- NCT02164513
- Testing
- fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
- Where
- 998 sites in United States, Argentina and 35 more
- Volunteers
- 10,355 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)
This study looks at data from people with chronic obstructive pulmonary disease (COPD). Some used Stiolto Respimat and the others Trelegy Ellipta as their first treatment for COPD.
- Trial name
- NCT05169424
- Testing
- Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg)
- Where
- United States
- Volunteers
- 9,117 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Aclidinium/Formoterol Fixed Combination Dose Finding Study
The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for investigation in Phase III clinical trials
- Trial name
- NCT00626522
- Testing
- Aclidinium bromide and formoterol
- Where
- 9 sites in Australia, Czechia and 2 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
COPD, COPD Exacerbation
Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
This will be a non-blinded feasibility (pilot) study comparing triple therapy nebulizer vs dry powdered inhalers (DPI) for care transitions in Chronic obstructive pulmonary disease (COPD) exacerbation patients.
- Trial name
- NCT03219866
- Testing
- Nebulizers, Dry Powder Inhaler, Brovana
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Chronic Obstructive Pulmonary Disease (COPD)
Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to see if treatment with AZD4818 for four weeks is tolerable, safe and effective in treating COPD and, if so, how it compares with placebo.
- Trial name
- TOP (NCT00629239)
- Testing
- AZD4818
- Where
- 12 sites in Denmark, Finland and 3 more
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, COPD
A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients
This study in Chronic Obstructive Pulmonary Disease (COPD) patients will investigate the bronchodilatory effect of AZD8683. AZD8683 will be tested versus placebo and an active comparator.
- Trial name
- NCT01708057
- Testing
- AZD8683, Tiotropium
- Where
- 6 sites in Poland, Sweden
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.